Login to Your Account



Other News To Note


Wednesday, July 11, 2012
• Chelsea Therapeutics International Ltd., of Charlotte, N.C., disclosed plans to reduce head count "significantly," retaining only employees needed to pursue FDA approval of Northera (droxidopa) for symptomatic neurogenic orthostatic hypotension (NOH) in patients with primary autonomic failure.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription